



12-26-01

Mibor Seg

Docket Number	4-31664A/USN
<u>FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10</u>	
EL91301396US Express Mail Label Number	December 19, 2001 Date of Deposit

Address to: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

ic979 U.S. PRO
10/024935
12/19/01

UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b) is the utility patent application of

Applicant (or identifier): BAIR ET AL.

Title: INHIBITORS OF THE E2F-1/CYCLIN INTERACTION FOR CANCER THERAPY

Enclosed are:

1. Specification (Including Claims and Abstract) - 37 pages

2. Drawings - sheets

3. Unexecuted Declaration and Power of Attorney (original or copy)

4. Microfiche Computer Program (appendix)

5. Nucleotide and/or Amino Acid Sequence Submission

Computer Readable Copy

Paper Copy

Statement Verifying Identity of Above Copies

6. Preliminary Amendment

7. Assignment Papers (Cover Sheet & Document(s))

8. English Translation of

9. Information Disclosure Statement

10. Certified Copy of Priority Document(s)

11. Return Receipt Postcard

12. Other: Application Data Sheet

Filing fee calculation:

- Before calculating the filing fee, please enter the enclosed Preliminary Amendment.
 Before calculating the filing fee, please cancel claims

Basic Filing Fee	\$ 740
Multiple Dependent Claim Fee (\$ 280)	\$
Foreign Language Surcharge (\$ 900)	\$
For	Rate
Number Filed	
Extra Claims	Total Claims 10 -20 0 x \$ 18 = \$
Independent Claims	1 -3 0 x \$ 84 = \$
	TOTAL FILING FEE \$ 740

- Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$740. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.


Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie
Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (908) 522-6955.

Date: December 19, 2001

Respectfully submitted,



Hesna J. Pfeiffer
Attorney for Applicants
Reg. No. 22,640
Tel. No. (908) 522-6940